









Markets
/
Stocks
/
nasdaq-lfvn
/

LifeVantage Corp

LFVN

5.030USD

+0.410+8.87%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

63.84MMarket Cap

7.98P/E TTM



LifeVantage Corp

5.030

+0.410+8.87%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of LifeVantage Corp

Currency: USD Updated: 2026-02-06

Key Insights

LifeVantage Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 69 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

LifeVantage Corp's Score

Industry at a Glance

Industry Ranking

69 / 159

Overall Ranking

184 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

LifeVantage Corp Highlights

StrengthsRisks

LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 228.53M.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 21.08%.

Undervalued

The company’s latest PE is 7.98, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 8.24M shares, decreasing 18.07% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 563.28K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.15.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.000

Target Price

+138.10%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of LifeVantage Corp is 7.71, ranking 99 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 48.93M, representing a year-over-year decrease of 27.79%, while its net profit experienced a year-over-year decrease of 89.18%.

Score

Industry at a Glance

Previous score

7.71

Change



Financials

7.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.13

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.65

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

LifeVantage Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of LifeVantage Corp is 8.24, ranking 24 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 7.98, which is 998.76% below the recent high of 87.64 and 1304.95% above the recent low of -96.11.

Score

Industry at a Glance

Previous score

8.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 69/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of LifeVantage Corp is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 14.50, with a high of 17.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.000

Target Price

+138.10%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

LifeVantage Corp

LFVN

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of LifeVantage Corp is 7.23, ranking 73 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 6.61 and the support level at 3.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.00

Change

0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.170

Sell

RSI(14)

38.363

Neutral

STOCH(KDJ)(9,3,3)

41.025

Buy

ATR(14)

0.563

Low Volatility

CCI(14)

-126.048

Sell

Williams %R

56.870

Sell

TRIX(12,20)

-0.683

Sell

StochRSI(14)

70.108

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

5.214

Sell

MA10

5.443

Sell

MA20

5.825

Sell

MA50

6.178

Sell

MA100

7.354

Sell

MA200

10.057

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of LifeVantage Corp is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 64.97%, representing a quarter-over-quarter decrease of 9.56%. The largest institutional shareholder is James Simons, holding a total of 852.02K shares, representing 6.66% of shares outstanding, with 2.96% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Capital Management Corporation

2.06M

+63.03%

Renaissance Technologies LLC

Star Investors

852.02K

-4.74%

Sudbury Capital Management, LLC

749.33K

BlackRock Institutional Trust Company, N.A.

679.12K

+25.38%

Fife (Steven R)

662.25K

-1.22%

The Vanguard Group, Inc.

Star Investors

561.11K

-0.58%

Radoff (Bradley Louis)

551.50K

-32.02%

Dimensional Fund Advisors, L.P.

292.57K

-0.12%

Mauro (Garry Paul)

257.82K

+1.00%

Geode Capital Management, L.L.C.

243.58K

-0.71%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of LifeVantage Corp is 3.70, ranking 99 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. LifeVantage Corp’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.